DE60229958D1 - Polymerstabilisierte proteinasen - Google Patents

Polymerstabilisierte proteinasen

Info

Publication number
DE60229958D1
DE60229958D1 DE60229958T DE60229958T DE60229958D1 DE 60229958 D1 DE60229958 D1 DE 60229958D1 DE 60229958 T DE60229958 T DE 60229958T DE 60229958 T DE60229958 T DE 60229958T DE 60229958 D1 DE60229958 D1 DE 60229958D1
Authority
DE
Germany
Prior art keywords
proteinases
polymer
stabilized
admixture
stabilization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60229958T
Other languages
English (en)
Inventor
Merry R Sherman
Alexa L Martinez
Shyam S Bhaskaran
L David Williams
Mark G Saifer
John French
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mountain View Pharmaceuticals Inc
Original Assignee
Mountain View Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mountain View Pharmaceuticals Inc filed Critical Mountain View Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60229958D1 publication Critical patent/DE60229958D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
DE60229958T 2001-06-28 2002-06-28 Polymerstabilisierte proteinasen Expired - Lifetime DE60229958D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89407101A 2001-06-28 2001-06-28
US10312802A 2002-03-22 2002-03-22
PCT/US2002/020417 WO2003002716A2 (en) 2001-06-28 2002-06-28 Polymer stabilized proteinases

Publications (1)

Publication Number Publication Date
DE60229958D1 true DE60229958D1 (de) 2009-01-02

Family

ID=26800115

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60229958T Expired - Lifetime DE60229958D1 (de) 2001-06-28 2002-06-28 Polymerstabilisierte proteinasen

Country Status (8)

Country Link
US (1) US7229810B2 (de)
EP (1) EP1421175B1 (de)
AT (1) ATE414711T1 (de)
AU (1) AU2002345938A1 (de)
CA (1) CA2450985A1 (de)
DE (1) DE60229958D1 (de)
DK (1) DK1421175T3 (de)
WO (1) WO2003002716A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020065397A1 (en) * 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
EP1476573B1 (de) 2002-01-28 2010-01-06 Ambion, Inc. Für den nachweis von nukleinsäuren kompetente biologische rohderivate
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
CA2525497A1 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Peptides that bind to the erythropoietin receptor
EP2336162A1 (de) * 2003-05-12 2011-06-22 Affymax, Inc. Neue polyethylenglycol-modifizierte Agoniste von Erythropoietin und deren Verwendungen
WO2004100997A2 (en) 2003-05-12 2004-11-25 Affymax, Inc. Spacer moiety for poly(ethylene glycol) -modified peptides
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP2008519858A (ja) * 2004-11-11 2008-06-12 アフィーマックス・インコーポレイテッド エリスロポエチンレセプターに結合する新規ペプチド
JP2008529516A (ja) * 2005-02-11 2008-08-07 インヴィトロジェン ダイナル エーエス エチレングリコール多量体の使用を含む核酸の単離方法
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US20070212865A1 (en) * 2006-03-08 2007-09-13 Craig Amrine Method for planarizing vias formed in a substrate
US7964350B1 (en) 2007-05-18 2011-06-21 Applied Biosystems, Llc Sample preparation for in situ nucleic acid analysis
EP2955233A1 (de) * 2008-12-19 2015-12-16 Life Technologies Corporation Proteinase K Inhibitore, Verfahren und Zusammensetzungen davon
JP2021517143A (ja) * 2018-03-14 2021-07-15 バ、ヨン Ｐｅｇ化不凍タンパク質およびそれを作製する方法およびそれを使用する方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
JPS5816685A (ja) 1981-07-22 1983-01-31 Takeda Chem Ind Ltd 固定化酵素，その製造法および製剤
JPS57118789A (en) 1981-01-13 1982-07-23 Eisai Co Ltd Modified streptokinase and its preparation
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4844897A (en) 1985-09-13 1989-07-04 Hiroshi Maeda Anti-tumor protease preparations
JPS6255079A (ja) 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
US5278062A (en) 1987-04-03 1994-01-11 Amgen Proteolytic enzymes
US5006333A (en) 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5246849A (en) 1988-04-12 1993-09-21 Enzon, Inc. Thermally stable serine proteases
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5498523A (en) 1988-07-12 1996-03-12 President And Fellows Of Harvard College DNA sequencing with pyrophosphatase
US4962020A (en) 1988-07-12 1990-10-09 President And Fellows Of Harvard College DNA sequencing
JPH02219571A (ja) * 1989-02-20 1990-09-03 Kanebo Ltd 修飾プロテアーゼ及びその製造法
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
HU223760B1 (hu) 1991-09-24 2005-01-28 Keygene N.V. Szelektív restrikciós fragmentumsokszorosítás, általános módszer DNS-fingerprint analízisére
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5482996A (en) * 1993-12-08 1996-01-09 University Of Pittsburgh Protein-containing polymers and a method of synthesis of protein-containing polymers in organic solvents
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CN1168694A (zh) 1994-12-07 1997-12-24 诺沃挪第克公司 具有减弱的变应原性的多肽
US5837517A (en) 1995-05-05 1998-11-17 Novo Nordisk A/S Protease variants and compositions
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
EP0932667B1 (de) 1996-11-04 2008-10-01 Novozymes A/S Subtilase varianten und verbindungen
US6416756B1 (en) * 1997-01-10 2002-07-09 Novozymes A/S Modified protease having 5 to 13 covalently coupled polymeric molecules for skin care
AU740207B2 (en) 1997-02-06 2001-11-01 Novozymes A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
CN100335624C (zh) 1997-06-25 2007-09-05 诺沃奇梅兹有限公司 一种被修饰多肽
US5847110A (en) * 1997-08-15 1998-12-08 Biomedical Frontiers, Inc. Method of reducing a schiff base
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
CA2333491A1 (en) * 1998-07-17 2000-01-27 Novozymes A/S A polypeptide-polymer conjugate with improved wash performance
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
RU2278680C2 (ru) 1998-08-06 2006-06-27 Маунтэн Вью Фармасьютикэлз, Инк. Способ изолирования тетрамерной формы уриказы и уриказа, полученная данным способом
US6964764B2 (en) * 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin

Also Published As

Publication number Publication date
EP1421175A2 (de) 2004-05-26
CA2450985A1 (en) 2003-01-09
DK1421175T3 (da) 2009-03-23
ATE414711T1 (de) 2008-12-15
WO2003002716A2 (en) 2003-01-09
US20030012777A1 (en) 2003-01-16
EP1421175A4 (de) 2004-12-08
WO2003002716A3 (en) 2003-10-16
US7229810B2 (en) 2007-06-12
AU2002345938A1 (en) 2003-03-03
EP1421175B1 (de) 2008-11-19

Similar Documents

Publication Publication Date Title
DE60229958D1 (de) Polymerstabilisierte proteinasen
CY1119742T1 (el) Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου
ATE542922T1 (de) 2'-terminator-assoziierte pyrophosphorolyse- aktivierte polymerisierung
NO20034751D0 (no) Antranilsyreamider, deres fremstilling og anvendelse samt preparater
WO2004022701A3 (en) Exponential amplification of nucleic acids using nicking agents
DE60329220D1 (de) Antisense-entwurf
DK1232502T3 (da) Magnetiske glaspartikler, fremgangsmåde til deres fremstilling samt anvendelser deraf
ATE469911T1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
ATE467681T1 (de) Zusammensetzungen und verfahren zur verwendung einer synthetischen dnase i
MXPA03002572A (es) Secuencias de nucleotidos que intervienen en la fertilidad de los machos y metodo de su uso.
BRPI0413967A (pt) polìmero solúvel em água, processo para preparar um polìmero solúvel em água, composição e solução aquosa
DE60216278D1 (de) Polyoxyalkylen-ammoniumsalze und ihre verwendung als antistatika
DZ3182A1 (fr) Solution acide sulfoisophtalique et procédé avec cette solution.
WO2002014485A3 (en) Kallikrein gene
WO2004096842A3 (en) Sars virus nucleotide and amino acid sequences and uses thereof
WO2020198509A3 (en) Modified oligonucleotides with increased stability
BR9904054A (pt) Proteìnas que se ligam a diarilsulfoniluréia
WO2000053776A3 (en) Human kallikrein-like genes
NO20024959D0 (no) Polyamidnukleinsyrederivater, midler og fremgangsmåter for deres fremstilling
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
WO2005047462A3 (en) Universal control for nucleic acid amplification
ATE369429T1 (de) Strukturproteine des virus, welches die pankreas- krankheit bei fischen verursacht, und ihre verwendungen
DE50110723D1 (de) Isolierte luziferasen sowie deren verwendung
DK1108786T3 (da) Hidtil ukendt kollektin
WO2001053352A3 (en) Sperm specific proteins

Legal Events

Date Code Title Description
8364 No opposition during term of opposition